Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Other Non-Current Assets (2021 - 2026)

Elicio Therapeutics filings provide 3 years of Other Non-Current Assets readings, the most recent being $2.8 million for Q4 2023.

  • On a quarterly basis, Other Non-Current Assets fell 1.16% to $2.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.8 million, a 1.16% decrease, with the full-year FY2023 number at $2.8 million, down 1.16% from a year prior.
  • Other Non-Current Assets hit $2.8 million in Q4 2023 for Elicio Therapeutics, roughly flat from $2.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q4 2022 to a low of $33000.0 in Q3 2021.
  • Median Other Non-Current Assets over the past 3 years was $96000.0 (2021), compared with a mean of $1.0 million.
  • The widest YoY moves for Other Non-Current Assets: up 3633.33% in 2023, down 1.16% in 2023.
  • Elicio Therapeutics' Other Non-Current Assets stood at $106000.0 in 2021, then soared by 2572.64% to $2.8 million in 2022, then decreased by 1.16% to $2.8 million in 2023.
  • The last three reported values for Other Non-Current Assets were $2.8 million (Q4 2023), $2.8 million (Q3 2023), and $2.8 million (Q2 2023) per Business Quant data.